Clinical Trial Search

Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of Product Administration — 3; 2; 2; 3 Participants

Primary: Number of Subjects Reporting Systemic Reactogenicity Signs and Symptoms Within 3 Days of Any Product Administration — 3; 3; 3; 2 Participants

Primary: Part 1:Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs) — 3; 2; 4; 3 Participants

Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms for 3 Days After VRC01LS or VRC07-523LS Administration — 7; 6; 0; 3 Participants

Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of CAP256V2LS Product Administration — 5; 4; 0; 1 Participants

Primary: Tolerability and Safety of the Treatment. — 0; 0 participants

Primary: Number of Participants Reaching Clinical Long Term Component Endpoints — 3; 5; 18; 23 Participants

Primary: Assessement of Safety — 0; 0 Participants

Primary: Number of Participants With Mucosal Binding IgG Antibodies to HIV CN54gp140 Antigen — 0; 3; 1; 6 Participants

Primary: Part 1: Maximum Change From Baseline in Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) at Day 11 — -8605.8; -100719.8; -3406.5 Copies per milliliter

Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms For 7 Days After Each Product Administration — 1; 1; 0; 0 Participants

Primary: Numbers of Treatment Related Side Effects (DLT = Reaction 3 or More) — 0; 0 side effects

Primary: Monotherapy: Maximum Change From Baseline in Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) — -1.17; -2.15; -2.31; -0.28 Copies per milliliter…

Primary: Primary Safety Endpoint — 7; 8; 10 Participants — p=>0.05

Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms Within 3 Days of N6LS Product Administration Alone or N6LS Co-Administered With rHuPH20 — 3; 1…

Primary: Adverse Events — 0; 0; 0; 0 participants experiencing adverse events

Primary: Number of Participants With Treatment-Emerging Adverse Events — 1; 1; 4; 3 Participants

Primary: The Rate of Related Adverse Events in Subjects Who Began cART During Acute or Early HIV-1 Infection. — 0; 0 Related Adverse Events

Primary: Number of Subjects With Any and Grade 3 Solicited Local Symptoms — 2; 0; 2; 49 Participants

Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness — 12; 11; 15; 8 Participants

Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness — 2; 2; 9; 12 Participants

Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms — 19; 18; 7; 15 Participants

Primary: Number of Participants With Moderate or Greater Reactogenicity (i.e., Solicited Adverse Events) — 2; 4 Participants

Primary: Part 1: Number of Participants With Adverse Events (AEs) — 3; 2; 1; 3 Participants

Primary: Hair Antiretroviral Imaging — 156.4826656; 1092.130868; 0.501209; 3942.692396 Signal Abundance (au)

Primary: Number of Grade 3 or Higher Adverse Events — 0 Events

Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms During the Vaccine Regimen — 16; 18; 16; 7 Participants

Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness — 3; 3; 3; 3 Participants

Primary: Part 1: Number of Participants With Any Adverse Events (AEs) and by Severity — 4; 2; 3; 0 Participants

Primary: Number of Subjects With Grade 3 Solicited Local Symptoms — 1; 0; 1; 0 Participants